Studies repeat radiation treatment to the chest in people with thoracic cancer
Follows people with chest cancers who receive a second course of high-dose radiation.
Plain-language title generated from the registry record
Registry title: Curatively Intended Thoracic Reirradiation
Key facts
- Where
- Aarhus, DenmarkSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who need a second course of high-dose radiotherapy to the chest, for lung cancer that came back, a new lung cancer, or a single spread tumour, with the aim of lasting local control.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Lung cancer that came back, a new primary lung cancer, or one single spread tumour in the chest. Cancer must be confirmed by biopsy, or by a team of specialists if no biopsy is available.
- Earlier treatment
- Must have had earlier radiotherapy to the chest (reirradiation type 1 or type 2). The digital dose plan of the earlier radiotherapy must be available.
Main reasons for not taking part
- Another cancer that is not under control
- Earlier and new radiotherapy planned at almost the same time
- Pregnancy
- Planned radiotherapy to a minimum CTV mean dose of 45 Gy for SCLC and 50 Gy for NSCLC and oligometastatic lesions
Read by machine on 9 November 2026.
Where in Denmark
- Aarhus University HospitalAarhus, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Aarhus
- Trial code
- NCT06950073
- Record updated
- 4 March 2026
- Original description
The number of long-term lung cancer (LC) survivors increases, however many patients are diagnosed with recurrent or new thoracic cancers. High-dose reirradiation (reRT) is promising but associated with high severe toxicity rates. Existing studies are small lacking high-quality data, with no clear correlation between toxicity risk and delivered radiotherapy (RT) dose.Read full original descriptionShow less
CUratively Intended Thoracic REirradiation: An Observational Study of High-dose Reirradiation of Thoracic Tumours: A Multicentre Prospective Registration Protocol
The number of long-term lung cancer (LC) survivors increases, however many patients are diagnosed with recurrent or new thoracic cancers. High-dose reirradiation (reRT) is promising but associated with high severe toxicity rates. Existing studies are small lacking high-quality data, with no clear correlation between toxicity risk and delivered radiotherapy (RT) dose.
This Danish multicentre prospective cohort study aims to provide a framework for collecting radiotherapy-related toxicity data, loco-regional control, and overall survival data for patients with thoracic cancer undergoing reirradiation; with the ultimate aim of providing safe reirradiation to more patients.
As a secondary aim, guidelines for dose accumulation and provisional constraints for the organs at risk will be used to establish a uniform treatment strategy for reirradiation.
The CURE Lung trial will provide high-impact, globally missing data. This project will ensure full utilization of and learning from the trial, adding SDM, PROMs, and modality referral to the trial. It will model the correlation between toxicity burden and doses, enabling individualized reRT with optimized dose prescription based on toxicity risk and patient preferences, and assisting in the decision-making on the prescription dose and optimal modality. This will ensure safe reRT for the increasing number of long-term LC survivors.
Inclusion: Radiotherapy of thoracic lesion(s) (loco-regional lung cancer recurrence, new primary lung cancer, or solitary oligo metastasis) with the aim of long-term local control; Reirradiation type 1 or type 2, i.e. previous radiotherapy to the thorax as per ESTRO-EORTC consensus definition of reirradiation [Andratschke 2022]. For the sake of this study, multiple treatments to the lungs will be classified as type 2 reirradiation; Verification of malignancy based on biopsy. If no biopsy is available, the decision of reirradiation should be agreed upon in a multidisciplinary conference; Available digital dose plan(s) from former radiotherapy course(s) (DICOM files) - note that multiple re-treatments are allowed; Adequate lung function to tolerate treatment, at the discretion of the treating physician; Ability to complete a radiotherapy course with the aim of local control; ECOG Performance status 0-2; Estimated life expectancy ≥ 6 months; Age ≥18 years; Signed informed consent.
Exclusion: Radiotherapy to a minimum CTV mean dose of 45 Gy for SCLC and 50 Gy for NSCLC and oligometastatic lesions. Treatment schedule according to local protocols and treating physician preference; Uncontrolled other malignancy; The primary and the reirradiation treatment may not be quasi-simultaneous (i.e. the two treatments should be planned independently); Pregnancy.